SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (2678)10/13/2011 12:20:47 PM
From: Biotech Jim  Read Replies (1) | Respond to of 3202
 
I am aware of tapering drugs in the treatment of anxiety and sleep disorders to alleviate the rebound effect. I am not aware of any such phenomenon in (broadly defined) hematologic disorders. Also, I wonder whether intracellular enzyme mechanisms are different in this regard than plasma membrane receptor mechanisms.

I am also concerned about the market size for ruxo in MF. Any news for INCY in RA will not move the stock much until after the Ruxo MF PDUFA date, and the readout of the Ph3 RA trials.